Medical Representative interview questions and answers

I would open with the doctor’s patient, not the brand: Doctor, for your type 2 diabetes patients who are not reaching their sugar targets on metformin alone, I would like to share a quick option. Then I would give the key message from the approved visual aid, for example a once-daily combination that adds a second mechanism of action, with the main benefit and the supporting study reference printed on the aid. I would mention the key safety points as given in the prescribing information. Then I would ask a question, such as which patients he would consider it for, and close by asking him to try it in a few suitable patients and give me feedback next visit.

The Uniform Code for Pharmaceutical Marketing Practices and the company’s own code set clear limits. In daily work, it means I do not give doctors or their families gifts, cash or personal benefits, and I do not offer travel or hospitality to influence prescribing. Free samples go only to doctors qualified to prescribe that product, in the permitted quantity, with proper records. Every claim I make must match the approved prescribing information and promotional material, so I never make comparisons or claims that are not in the approved aid, and I do not promote any use outside the approved indication. Any doubt I check with my manager or the compliance team.

I would thank the doctor and take it seriously, without arguing about whether the product caused it. I would note the basic details the company’s form needs: the patient’s age and sex or initials, the product and dose, when the reaction started, what happened and what was done, and the doctor’s contact details. I would not collect more personal information than required. Then I would report it to the company’s pharmacovigilance team within the timeline in our SOP, which is usually within one working day of hearing about it. I would tell the doctor the safety team may contact him for more information, and I would not give medical advice myself.

I start from my master doctor list and classify doctors by potential, based on patient flow for our therapy area, current prescribing of our brands and competitors, and RCPA data. High-potential doctors are visited more often, for example two or three times a month, and others once. I divide the territory into areas so each day covers one cluster without wasting travel time. My tour programme follows the company’s call average target, and I include chemists and stockists along the way. Every evening I report calls in the CRM app and note follow-ups for the next visit, such as samples promised or questions to answer.

RCPA stands for retail chemist prescription audit. I visit chemists near my key doctors and, with their cooperation, check which brands the doctor has prescribed for our therapy area over a period. This shows whether a doctor who says he prescribes our brand actually does, and which competitor brands he uses. If a doctor is writing a competitor for most patients, I plan my detailing around the reason, perhaps a dosage convenience or price question. I also check that chemists stock our brand, because a prescription is lost if the patient cannot find it. I track RCPA monthly for my top doctors and share it with my manager.

Primary sales are the company’s sales to stockists, usually through the company’s depot or carrying and forwarding agent. Secondary sales are the stockists’ sales to retail chemists and hospital pharmacies, which show real movement in the market. As an MR, I need both. I check stock at key chemists near my doctors, especially for newly prescribed brands, and if stock is missing, I take an order and pass it to the stockist. I also visit stockists to review stock levels, expiry and pending orders. Good secondary sales mean doctors’ prescriptions are being filled and the stockist will reorder from the company.

Take ACE inhibitors, such as enalapril or ramipril. The body has a system called the renin-angiotensin system that controls blood pressure. Angiotensin-converting enzyme changes angiotensin I into angiotensin II, which narrows blood vessels and makes the body hold on to salt and water. ACE inhibitors block that enzyme, so less angiotensin II is formed, blood vessels relax and blood pressure falls. A common side effect is a dry cough, which happens because the enzyme also breaks down a substance called bradykinin. That is why some patients are switched to ARBs, like telmisartan, which block the angiotensin II receptor instead.

I would acknowledge it honestly: Yes, Doctor, our brand is priced a little higher. Then I would focus on what is genuinely supported. That may be our manufacturing quality and stability data, a convenient pack size or strength that improves adherence, consistent availability at chemists in his area, or patient support material. I would not say anything negative about the competitor that I cannot prove. If the price gap is a real concern for his patients, I would mention our lower-priced pack where one exists. Then I would ask whether there are specific patients for whom these factors matter, so he can try our brand where it fits best.

I complete the training modules the company releases for each product, and I revise the prescribing information whenever there is an update. Before a cycle, I practise the detailing with my manager. I also read the key studies listed in our approved literature, so I understand the patient population, the endpoints and the limitations. With doctors, I use only the approved study reprints or leave-behinds and present the data accurately, including what the study did not show. If a specialist asks detailed questions beyond my knowledge, I note them and request a response from our medical affairs team rather than guessing.

First, I would go through the handover with my manager and the previous MR if possible: the doctor list, prescription history, key chemists, stockists and pending issues. In the first two weeks, I would meet all high-potential doctors and introduce myself, focusing on listening to their needs and any complaints about service. I would visit every stockist to check stock, expiry and outstanding issues. I would do RCPA at the key chemists to see the real prescription status. By the end of the month, I would have a clear list of opportunities and gaps, and a revised tour programme agreed with my manager.

I would first get the topic, speaker and budget approved through the company’s process, with medical affairs or the compliance team reviewing the content. The speaker would be a qualified specialist presenting balanced scientific information. I would invite doctors relevant to the topic, choose a modest venue that suits a learning event, and avoid anything that looks like entertainment or a gift. Any refreshments would be modest and as allowed by the company policy. I would keep records of attendance, the agenda and expenses. After the meeting, I would follow up with doctors who asked questions.

A consultant physician in my territory used a competitor’s antidiabetic brand for most patients and gave me less than a minute per visit. Over three visits, I asked short questions and learned his concern was patients stopping treatment because of stomach upset. Our brand had an extended-release form with a supporting tolerability study in the approved literature. I shared that summary and requested he try it in a few new patients. I followed up after two weeks and checked with nearby chemists that stock was available. Over the next two months, RCPA showed him prescribing our brand regularly for new patients.

Midway through a month I was at about forty percent of my target because one large hospital’s pharmacy had delayed its orders. I first spoke to the purchase officer and found the issue was a pending rate approval, which I escalated to my manager to resolve. Then I focused on high-potential doctors in my core territory, increased calls on them and ran RCPA to find chemists where our brands were out of stock. I avoided loading stockists with extra stock, since that only causes returns and expiry later. I ended the month at around ninety-five percent and the hospital order came through the next month.

A doctor told me he would prescribe more of our brand if we sponsored his family’s holiday. I thanked him for his support, then explained politely that our company and the industry code do not allow us to provide travel or personal benefits to doctors, and that I could lose my job for it. I offered what I could genuinely provide: scientific updates, approved patient education material and information about our CME programmes. He was annoyed at first, but he still met me on later visits. I informed my manager of the request, as our policy requires.

A busy paediatrician in my area saw medical reps only after his OPD, and the wait was often over an hour. Instead of wasting the time, I used it to do RCPA at the chemist next door and update my call reports on the app. When I finally met him, I kept my detailing to one focused message and a short question about his patients, so he did not feel the delay was my fault. He noticed I was always brief and well prepared, and later started giving me a fixed time on Saturdays, which saved hours every month.

During a joint working day with my area manager, we made twelve doctor calls. In the evening, he told me that my detailing was accurate but that I was talking too much and not asking doctors questions about their patients. I agreed, because some doctors had looked impatient. Over the next few weeks, I practised opening every call with one question about the doctor’s patients and keeping the main message under a minute. On his next visit, he noted that doctors were engaging more, and my call quality score in the next review improved.

During my B.Pharm, our class wanted to organise a health awareness camp, but the principal was worried about cost and safety. I collected data on similar camps run by nearby colleges, prepared a simple budget with sponsorship from a local pharmacy, and listed the safety measures, including a supervising doctor. I presented it in five minutes and answered his questions. He approved it. The camp screened over two hundred people for blood pressure and blood sugar. It taught me that a short, well-prepared case with facts convinces people more than enthusiasm alone.

Yes. I have a valid two-wheeler licence and my own vehicle, and I am comfortable riding in the city and nearby towns. I understand that field work means visiting doctors, chemists and stockists across the territory, sometimes with outstation days. I am willing to relocate to the headquarters town of the territory. I would like to know the daily allowance and travel allowance structure, so I can plan my expenses, but the travel itself is not a concern.

I understand that MR compensation usually has a fixed salary, a daily allowance for field work, a travel allowance, and incentives linked to achieving targets. As a fresher with a B.Pharm, I would expect the standard starting package your company offers for this level. I am more focused on the incentive structure and training, because I am confident I can earn well through performance. I would like to understand how targets are set and how incentives are calculated, so I can plan for them from my first month.

I have spent three years with a large company, selling mostly mature brands in a crowded market. Your company is growing in cardiology and diabetes, with several newer combinations, which means real scientific detailing and a chance to build brands rather than just maintain them. I also know your field force is smaller, so good performers get noticed and can move to a manager role sooner. I spoke to a few chemists in my area, and they said your supply is reliable, which matters a lot in the field.